York Capital

• York Capital in its acquisition of Precise Medical Solutions LLC, a medical aesthetics and wellness provider offering weight loss and cosmetic treatment services
• York Capital in its acquisition of NMA Super Holdings, LLC (Neuromonitoring Associates), a provider of intraoperative neuromonitoring services focused on patient safety during surgery

See less

Ian has served as legal counsel in numerous multibillion-dollar and middle-market private investment fundraisings for institutional and boutique sponsors across a spectrum of investment strategies, including buyout, real estate, loan origination, debt, credit, fund of fund, healthcare, infrastructure, region specific, secondary, venture, growth equity, distressed/special situation, energy, funds-of-one, seeding, and co-investment. He also has extensive experience advising investment firms and private equity sponsors on hybrid, semi-open ended, and other bespoke fund structures that align the fund’s liquidity profile and terms to the liquidity and characteristics of the underlying investments.

He also regularly assists fund sponsors with their internal operational matters, such as the organization and documentation of their firm governance arrangements, carry plan structuring, and employee co-investment vehicles and structures. Ian also counsels fund managers on a wide range of regulatory and compliance matters.

Ian is ranked as a leading investment funds lawyer by numerous publications, including Chambers and Partners, Legal 500 US, and IFLR1000.

In addition to fund sponsors, Ian’s clients include top institutional limited partners, family offices, sovereign wealth funds, and senior investment professionals.

See less

• Represented WhiteHorse Capital, a credit arm of H.I.G. Capital, in the formation of H.I.G. WhiteHorse Direct Lending Fund – 2020, which had aggregate capital commitments of approximately $1.65 billion
• Represented 3 Boomerang Capital in the formation of its flagship fund, 3 Boomerang Capital I, which had more than $375 million in capital commitments, exceeding its target
• Represented Speyside Equity Fund I LP and Speyside Equity Opportunity Fund LP in a single-asset continuation vehicle transaction to support future growth initiatives at portfolio company, Opta Group LP
• Represented H.I.G. Capital in the formation of its fourth US realty partners fund, H.I.G. Realty Partners IV, which closed with aggregate capital commitments of $838 million, exceeding its target
• Represented Boyne Capital in the formation of BCM Fund II, LP
• Represented H.I.G. Capital in the formation of H.I.G. Europe Realty Partners II, which had aggregate capital commitments of €673 million* ($760 million), exceeding its target
• Represented Martis Capital in the formation of Martis Partners III, LP, which had aggregate capital commitments of $545 million
• Represented H.I.G. Capital in the formation of H.I.G. Europe Middle Market LBO Fund, which closed with aggregate capital commitments of €2 billion
• Represented H.I.G. Capital in the formation of H.I.G. Realty Partners III, which closed with aggregate capital commitments of approximately $593 million
• Represented Lorient Capital in the fund formation and closing of Lorient Healthcare Fund II, which was oversubscribed and closed at its hard cap with aggregate capital commitments of $225 million
• Represented H.I.G. Capital in the formation of H.I.G. Europe Capital Partners III, which closed with aggregate capital commitments of €1.1 billion, exceeding its target
• Represented H.I.G. Capital in the formation of H.I.G. Middle Market LBO Fund III, LP, which closed with aggregate capital commitments of $3.1 billion, exceeding its target

See less

Steven is a recognized authority in national reimbursement strategy, enabling clients to maximize the value of healthcare services and products. His counsel is particularly sought after by executive leadership teams and general counsel in hospital systems, as well as by professional groups; pharmacy service providers; clinical laboratories; and manufacturers of pharmaceuticals, medical devices, and durable medical equipment. He has extensive experience in advising on cutting-edge regulatory developments and innovative business models, ensuring his clients remain competitive and compliant.

Core Areas of Experience:

• Healthcare Mergers and Acquisitions (M&A). Guiding transactions involving changes of ownership and control with a focus on seamless regulatory coordination
• Federal Healthcare Oversight. Managing audits, investigations, and compliance with federal programs
• Third-Party Payer and Reimbursement. Addressing challenges and opportunities in payer participation and payment structures
• Medicare Administrative Appeals. Driving favorable outcomes in high-stakes appeals
• Sector-Specific Regulations. Navigating the nuanced regulatory requirements of health facilities, corporate practice, pharmacy, clinical laboratories, hospice care, and pharmaceutical/device manufacturing
• Pharmacy Matters. Counseling pharmacies on state and federal regulatory frameworks, Medicare enrollment disputes, and revocations

Steven has also cultivated a niche practice in navigating the complexities of the 340B Drug Pricing Program, providing tailored guidance on program development, audit response, manufacturer repayments, and litigation. His ability to resolve intricate issues relating to duplicate discounts and alleged diversion has earned him accolades from healthcare providers and pharmacy services providers alike.

Thought Leadership

Steven’s thought leadership has been widely recognized, with accolades from Chambers USA and other prestigious legal directories. He is a sought-after speaker at industry conferences, addressing topics ranging from healthcare M&A trends to reimbursement innovation. His insights have also been featured in leading publications, and he frequently mentors the next generation of legal talent in the healthcare sector.

See less

• Represented a nationally recognized specialty physician group in its appeal of Medicare reimbursement rates resulting in underpayments exceeding $10 million over multiple years
• Represented multiple national pharmacy chains in their successful appeal of Medicare revocations following site visits identifying noncompliance with Medicare conditions of participation
• Advised multiple diversified health systems on the implementation and growth of pharmacy service lines and 340B contract pharmacy opportunities and access
• Represented several 340B covered entities in structuring 340B Drug Pricing Programs and appealing adverse Health Resources and Services Administration audit findings

See less

Thomas is a former chair of the Firm’s Global M&A Practice.

See less

• Represented a US-based PE sponsor in various transactions including the sale of its majority interest in a global specialty chemicals company headquartered in Europe to a European PE fund, a single-asset continuation fund transaction involving a global performance materials and specialty chemicals company with a major secondaries investor and various portfolio company transactions
• Represented a European life sciences company in various acquisitions, disposals and joint ventures including the $725 million acquisition of a pharmaceutical container business and a worldwide joint venture for life sciences products and the sale of its worldwide pharmaceutical glass tubing operations to and joint venture with a major US based glass and materials science company
• Represented a major Japanese trading company in investments in the US health care industry
• Represented one of the largest beverage companies in South America in a complex transaction with a global beer company involving the termination of a license to a prominent beer brand in consideration for payments of $400 million plus the transfer of rights to seven prominent beer brands
• Represented one of the leading US aluminum companies in its acquisition of one of the largest US aluminum rolling mills in a complex carve-out transaction valued at $670 million
• Represented a major European commodities trading company in its $400 million investment in a US coal mine valued in excess of $1.5 billion
• Represented a leading European packaging company in its $750 million acquisition of a global plastics packaging business, its joint venture with a leading US-based metals closure company and the euro 1.7 billion sale of its global PET and metal closure business
• Represented a European coal company in the $1.1 billion acquisition of one of the largest US-based coal producers and the $1 billion sale of its US and Australian coal mines to a private equity consortium
• Represented a leading European energy and industrials conglomerate as worldwide regulatory counsel in its announced $8.6 billion merger with a Swiss industrials group (terminated) and as U.S. counsel in its $14 billion merger with a German energy and industrials company and subsequent $2.8 billion divesture of its global aluminum business and its $700 million divestiture of its global packaging business.

See less

• Nominated as Lawyer of the Year by The Deal, 2018
• Nominated for Dealmaker of the Year by M&A Advisor with respect to Evonik’s $3.8 billion acquisition of the global performance materials division of Air Products and Chemicals, 2017
• Acritas Star Lawyer, 2016 to 2020 (noting his high level of expertise, strong advocacy skills and pragmatic approach)
• Chambers USA, 2006 to 2014 (noting his experience, practicality and perfect understanding of different legal cultures)
• Client Choice Awards 2016, sole winner in the M&A category (New York)
• Law and Politics, Super Lawyer for M&A international business transactions
• The Legal 500 United States, 2009, 2010, 2011, 2013, 2014, 2017, 2018 (noting his exceptional work and creativity in structuring many transactions)
• Super Lawyers, 2006 to 2008, 2011 to present

See less

Elizabeth co-leads the Firm’s Institutional Sexual Misconduct Response Team (SMRT). This team specializes in handling all aspects of investigations and litigation involving allegations of sexual assault, abuse and misconduct. She has a proven track record of success, including a recent series of victories in which her clients were dismissed from New York Child Victims Act cases early in the proceedings. She is well versed in the evolving revival legislation across the country that provides limited periods for sexual abuse survivors to file otherwise time-barred civil claims, including the New York Child Victims Act and Adult Survivors Act. Elizabeth is skilled at managing crises, protecting her clients’ reputations and approaching sexual misconduct cases with care and sensitivity—making her a trusted advisor to clients navigating these matters.

Elizabeth is experienced in all phases of litigation in state and federal courts, as well as in domestic arbitration, including pre-filing investigation and case assessment, fact and expert discovery, legal research, motion practice, trial preparation, trial and appeals. She has vigorously defended clients in investigations from regulatory and criminal enforcement agencies and is experienced in conducting internal investigations to help clients detect and address problems before they result in formal government inquiries or litigations. Her comprehensive investigation and litigation experience enables her to effectively conduct Title IX investigations and litigations as well. Additionally, she counsels clients on compliance issues and works with them to develop and implement compliance programs.

Elizabeth is the Chair of the Boston Women’s Committee and serves on the Firm’s Gender Diversity Committee. She also has an active pro bono practice, including conducting an independent investigation of a deadly COVID-19 outbreak at a veterans’ home.

While in law school, Elizabeth was a judicial intern for the Hon. Judith G. Dein in the US District Court for the District of Massachusetts. She was also the executive comments editor for the Boston College Law Review and admitted to the Order of the Coif.

See less

He also works extensively with family offices on family office formation, administration, and governance matters. Jay blends his real-world knowledge, technical expertise and practical approach to achieve clients’ goals as simply and efficiently as possible.

See less

• Negotiated many valuation issues with the Internal Revenue Service (IRS), including art valuations, blockage discounts, lack of marketability, lack of control and minority interest discounts
• Administered many estates ranging in total value from $50 million to multiple billions, with most estates involving many asset classes and assets in multiple jurisdictions
• Worked with numerous families on all aspects of their family offices, including formation, administration, tax planning, and succession matters
• Represented numerous clients in contested and uncontested guardianship proceedings, and trust and estate controversies

See less